- Firm’s industry-first expertise addresses continual low again ache
- Aclarion secured its first industrial settlement with Michigan’s Sheridan Neighborhood Hospital
- PRISM Rising Medical Gadgets Index options firms at forefront of innovation and market disruption in medtech
NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) — PRISM MarketView, a number one supplier of market insights and firm information, is worked up to announce that Aclarion, Inc. (NASDAQ: ACON) has been added to the PRISM Rising Medical Gadgets Index, which highlights firms on the forefront of innovation and market disruption within the medtech sector. Aclarion’s modern AI-driven diagnostic options for continual low again ache place the corporate as a standout within the evolving medical gadgets sector.
The U.S. medical gadgets market is projected to develop considerably, reaching an estimated worth of practically $315 billion by 2032. This growth is pushed by growing R&D investments and a sturdy pipeline of improvements, together with Aclarion’s NOCISCAN expertise, which affords the primary noninvasive, AI-supported diagnostic instrument for figuring out painful discs in sufferers affected by continual low again ache.
Decrease again ache is without doubt one of the largest healthcare expenditures in the USA, with the marketplace for lumbar spine diagnostics and remedy estimated at $40 billion yearly and general prices reaching as much as $134.5 billion. Aclarion’s NOCISCAN expertise addresses this rising want by providing a noninvasive diagnostic different.
Aclarion Standouts:
- Business-First Noninvasive Diagnostic: Aclarion’s NOCISCAN expertise is the primary of its variety, offering a noninvasive different to conventional diagnostics and delivering improved surgical outcomes for sufferers with decrease again ache.
- Robust Market Validation: Aclarion is addressing one of many world’s largest and costliest well being challenges—degenerative spine ailments and decrease again ache, affecting 266 million sufferers globally. The corporate’s confirmed expertise, together with newly established regulatory pathways and payer protection, is paving the best way for broader international adoption and driving robust market validation.
- Partnerships and Agreements: Aclarion secured its first industrial settlement in Michigan with Sheridan Neighborhood Hospital, bringing NOCISCAN to central Michigan. As well as, the corporate prolonged its industrial settlement with The London Clinic, growing entry all through the London market. Aclarion has additionally secured non-public payer protection from main UK insurers, together with AXA, Aviva and Vitality, offering entry to 60% of personal medical health insurance sufferers in better London. Yesterday, the corporate introduced the launch of a program to develop a statewide community of suppliers in New Jersey to make the most of NOCISCAN all through the private injury and staff’ compensation inhabitants.
- Scientific Proof: Aclarion’s expertise is supported by robust medical knowledge, demonstrating an 85% enchancment in sufferers handled based mostly on NOCISCAN diagnostics. A number of medical trials are at present underway, together with the CLARITY trial, which is ready to enroll as much as 300 sufferers. Affected person enrollment is anticipated to start in This fall 2024, with interim knowledge out there by Q1 2026 and full knowledge by Q2 2026. The corporate is actively conducting extra trials to additional validate the efficacy of its expertise.
For extra info on Aclarion and the PRISM Rising Medical Gadgets Index, go to prismmarketview.com.
About Aclarion, Inc.
Aclarion is a healthcare expertise firm that leverages magnetic resonance spectroscopy (“MRS”), proprietary sign processing strategies, biomarkers and augmented intelligence algorithms to optimize medical remedies. The Firm is first addressing the continual low again ache market with NOCISCAN, the primary, evidence-supported SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. By way of a cloud connection, NOCISCAN receives magnetic resonance spectroscopy knowledge from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing strategies extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, NOCISCAN gives important insights into the situation of a affected person’s low again ache, giving physicians readability to optimize remedy methods. For extra info, please go to www.aclarion.com.
About PRISM MarketView
Established in 2020, PRISM MarketView is devoted to the monitoring and evaluation of small cap shares in burgeoning sectors. We ship up-to-the-minute monetary market information, present complete investor instruments and foster a dynamic investor group. Central to our choices are proprietary indexes that observe rising sectors, together with biotech, clear vitality, next-generation tech, medical gadgets and past. Go to us at prismmarketview.com and observe us on Twitter.
PRISM MarketView doesn’t present funding recommendation.
Disclaimer: This communication was produced by PRISM MarketView, an affiliate of PCG Advisory Inc., (collectively “PCG”). PCG shouldn’t be a registered or licensed broker-dealer nor funding adviser. No info contained on this communication constitutes a proposal to promote, a solicitation of a proposal to purchase, or a advice of any safety. PCG could also be compensated by respective purchasers for publicizing info referring to its purchasers’ securities. See www.pcgadvisory.com/disclosures.
Contact:
PRISM MarketView
information@prismmarketview.com
646-863-6341
A photograph accompanying this announcement is out there at https://www.globenewswire.com/NewsRoom/AttachmentNg/9a4c45b4-63ec-4049-a7b8-16369cff9c9a
Discussion about this post